Authors : Jigneshkumar Jayantibhai Patel

Volume/Issue : Volume 11 - 2026, Issue 2 - February

Google Scholar : https://tinyurl.com/jvdhxrjs

Scribd : https://tinyurl.com/yc33feka

DOI : https://doi.org/10.38124/ijisrt/26feb1278

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Over the decades, I've seen respiratory viruses evolve from seasonal nuisances to global catastrophes, reminding us time and again of our vulnerabilities. This review draws from historical pandemics like the 1918 Spanish flu, which claimed 50-100 million lives, to the recent COVID-19 saga with its 7 million reported deaths. We delve into the staggering morbidity—2.4 million deaths and 3.6 million hospitalizations in 2016 alone, disproportionately hitting low- and middleincome countries. Advances in multiplex PCR panels, such as BioFire and QIAstat-Dx, have sharpened our diagnostic edge, while whole-genome sequencing (WGS) via platforms like Illumina and Oxford Nanopore aids in tracking variants and outbreaks. Vaccines for influenza, SARS-CoV-2, and RSV offer hope, but limited antivirals and rising resistance mutations (e.g., H275Y in influenza neuraminidase) demand caution. In India, where resources are stretched, we must prioritize expanding diagnostic labs, adult vaccination policies, genomic surveillance, local R&D, and infection control. This isn't just academic—it's a call to action based on years of frontline experience in tropical settings where these viruses hit hardest.

Keywords : Respiratory Viruses; Influenza Pandemics; SARS-CoV-2; Multiplex PCR; Whole-Genome Sequencing; Antiviral Resistance; Vaccination Strategies; Pandemic Preparedness; India Public Health.

References :

1. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis. 2006;12(1):15-22.
2. Viboud C, Simonsen L, Fuentes R, et al. Global mortality impact of the 1957-1959 influenza pandemic. J Infect Dis. 2016;213(5):738-745.
3. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687-695.
4. World Health Organization. Coronavirus disease (COVID-19) pandemic. Accessed February 10, 2026. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
5. Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory syndrome. N Engl J Med. 2003;349(25):2431-2441.
6. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-1820.
7. GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191-1210.
8. BioMérieux. FilmArray Respiratory Panel. Product information. 2024.
9. QIAGEN. QIAstat-Dx Respiratory Panel. Product brochure. 2023.
10. Centers for Disease Control and Prevention. Influenza vaccination: a summary for clinicians. 2025-2026 season.
11. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615.
12. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837-846.
13. Illumina. Sequencing platforms. Accessed January 2026. https://www.illumina.com/systems/sequencing-platforms.html.
14. Oxford Nanopore Technologies. MinION: portable sequencer. Product details. 2025.
15. Centers for Disease Control and Prevention. Antiviral drugs for influenza. 2025 summary.
16. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383(19):1813-1826.
17. Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586-1593.
18. Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740-746.
19. American Academy of Pediatrics Committee on Infectious Diseases. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415-420.
20. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913-923.
21. Mishin VP, Patel MC, Chesnokov A, et al. Susceptibility of influenza A, B, C, and D viruses to baloxavir. Emerg Infect Dis. 2019;25(10):1969-1972.
22. Hurt AC, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017. Antiviral Res. 2018;157:38-46.
23. Jones JC, Pascua PNQ, Fabrizio TP, et al. Influenza A and B viruses with reduced baloxavir susceptibility remain susceptible to approved neuraminidase inhibitors. Antimicrob Agents Chemother. 2022;66(1):e01329-21.
24. Gubareva LV, Mishin VP, Patel MC, et al. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveill. 2019;24(3):1800666.
25. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-150.
26. Indian Council of Medical Research. INSACOG: Indian SARS-CoV-2 Genomics Consortium. Annual report 2025.
27. Government of India. Integrated Disease Surveillance Programme (IDSP). Guidelines 2024.
28. World Health Organization. Global Influenza Surveillance and Response System (GISRS). Accessed February 2026.
29. Sharma DK, Patel A. Challenges in respiratory virus management in rural India: a perspective. Indian J Microbiol. 2024;62(4):567-578.
30. Troeger C, Blacker B, Khalil IA, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(11):1133-1161.